Holding spacers versus nebulisers for short activated beta-agonist treatment of acute asthma in children

Holding spacers versus nebulisers for short activated beta-agonist treatment of acute asthma in children - Spacers vs nebulisers for SABA treatment of acute asthma in children

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032560

Enrollment

100

Registered

2018-05-11

Start date

2018-05-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma in children

Interventions

Inhale 10mcg procaterol using spacer. Inhale 0.3mL procaterol and 2mL saline using nebuliser.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: *Physician diagnosed asthma(more than 2 wheeze episode) *Acute athsma attack(MPIS 1-13)

Exclusion criteria

Exclusion criteria: *Respitory infection of RS virus and human metapneumovirus *Respitory disease without asthma *Chromosomal anomary *Heart disease *History of low birth weight or preterm infant

Design outcomes

Primary

Measure	Time frame
Change in MPIS(modified pulmonary index score) by SABA treatment in asthma attack	—

Secondary

Measure	Time frame
Change in NRS(numerical rating scale) by SABA treatment Additional treatment including medication of systemic steroid Recoming to hospital by same problem in a week Time to stay in hospital *Adverse Event including increasing HR	—

Countries

Japan

Contacts

Public ContactDaisuke Hayashi

Tsukuba Medical Center Hospital Department of Pediatrics

hayashi_daisuke@tmch.or.jp0298513511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026